Dyne Therapeutics appoints Erick Lucera as CFO; outgoing CFO Richard Scalzo to consult

Dyne Therapeutics, Inc.

Erick Lucera named CFO and Treasurer, effective March 31, 2025; previously CFO of Editas Medicine and AVEO Pharmaceuticals.
Lucera receives base salary $520k, bonus up to 40%, and inducement equity: 214,500 stock options + 66,100 RSUs.
Richard Scalzo steps down as SVP Finance & Treasurer same date; will provide consulting services for up to 6 months.
Scalzo's unvested equity to continue vesting during consultancy; stock option exercise period extended to 6 months post-consulting.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Erick Lucera

Chief Financial Officer and Treasurer

DYN · Dyne Therapeutics, Inc.

Effective: 2025-03-31
Filed: March 20, 2025, 7:59 PM ET

On March 20, 2025, Dyne Therapeutics, Inc. (the “Company”) announced that its Board of Directors (the “Board”) had appointed Erick Lucera as Chief Financial Officer and Treasurer of the Company, effective as of March 31, 2025 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erick Lucera was appointed as Chief Financial Officer and Treasurer at Dyne Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer and Treasurer

Exact text from the filing

On March 20, 2025, Dyne Therapeutics, Inc. (the “Company”) announced that its Board of Directors (the “Board”) had appointed Erick Lucera as Chief Financial Officer and Treasurer of the Company, effective as of March 31, 2025 (the “Effective Date”).

View on SEC.gov

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-058979

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.